var data={"title":"Levofloxacin (United States: Not available) (oral inhalation): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levofloxacin (United States: Not available) (oral inhalation): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/794104?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levofloxacin-united-states-not-available-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levofloxacin (United States: Not available) (oral inhalation): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538446\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Quinsair</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538447\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Fluoroquinolone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538485\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis:</b> Inhalation: 240 mg every 12 hours in alternating cycles of 28 days on treatment followed by 28 days off treatment. Safety and efficacy of use beyond 6 months (3 consecutive cycles) have not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991538\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;20 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;20 mL/minute: Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988589\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538486\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50694805\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulaization Solution, Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Quinsair: 240 mg/2.4 mL (2.4 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538553\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538550\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhalation:</b> Inhale over ~5 minutes using nebulizer handset recommended by manufacturer (see product labeling). Do not mix levofloxacin with other medications. In patients taking multiple inhaled therapies, recommended order of administration is: bronchodilators, dornase alfa, airway clearance techniques, levofloxacin, inhaled steroids. If acute asymptomatic bronchospasm occurs after levofloxacin administration, may use a short-acting inhaled bronchodilator &ge;15 minutes to &le;4 hours prior to subsequent doses of levofloxacin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538448\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note: </b>Not approved in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis:</b> Management of cystic fibrosis in patients 18 years and older with chronic pulmonary <i>Pseudomonas aeruginosa</i> infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Safety and efficacy not demonstrated in patients with FEV<sub>1</sub> &lt;25% or &gt;85% predicted, or patients colonized with <i>Burkholderia cepacia</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537812\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">LevoFLOXacin may be confused with levETIRAcetam, levodopa, Levophed, levothyroxine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46576303\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>This product can produce systemic exposure to levofloxacin. See systemic levofloxacin for additional reactions.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (31%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest discomfort (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (2%), headache (1%), speech disturbance (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3%), vomiting (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (10%), increased bronchial secretions (5%), hemoptysis (3%), respiratory congestion (2%), thickening of bronchial secretions (2%), discoloration of sputum (1%), dyspnea (1%), paranasal sinus hypersecretion (1%), reduced forced expiratory volume (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal alanine aminotransferase, abnormal aspartate transaminase, abnormal hepatic function tests, aphonia, arthropathy, blurred vision, bronchospasm, burning sensation of skin, chest pain, cluster headache, costochondritis, decreased appetite, decreased exercise tolerance, decreased lung function (pulmonary function test decreased), diarrhea, dizziness, dysphagia, dyspnea on exertion, ECG abnormality (QRS complex abnormal), epistaxis, feeling hot, fever, flu-like symptoms, fungal infection (oral), gastroesophageal reflux disease, increased appetite, increased serum creatinine, insomnia, jitteriness, joint stiffness, limb pain, lower respiratory tract infection, migraine, muscle fatigue, nasal congestion, nasal mucosa irritation, nasopharyngitis, neuralgia, obstructive pulmonary disease, onychomycosis, oral candidiasis, oral discomfort, oropharyngeal pain, pharyngeal erythema, plantar fasciitis, pruritus, rales, retching, rhinorrhea, sinus headache, skin blister, sneezing, strain, sunburn, tendonitis, throat irritation, tunnel vision, upper abdominal pain, urine discoloration, vulvovaginal infection, weight loss, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538453\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to levofloxacin, other quinolones, or any component of the formulation; history of tendonitis or tendon rupture associated with use of any quinolone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538459\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: <b>[Canadian Boxed Warning]: Fluoroquinolones may prolong QTc interval</b> and have infrequently caused arrhythmia; systemic use of levofloxacin has been associated with torsades de pointes (rare). Avoid use in patients with a history of QTc prolongation, significant bradycardia, cardiomyopathy, myocardial ischemia, uncorrected hypokalemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Bronchospasm may occur. If acute, symptomatic bronchospasm occurs after administration, patient may benefit from use of a short-acting bronchodilator prior to subsequent doses; discontinue use if an allergic reaction is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cough: Cough may occur; consider use of alternative therapy in patients with continued therapy-induced cough.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Toxic psychosis, increased intracranial pressure (including pseudotumor cerebri), tremor, restlessness, anxiety, lightheadedness, dizziness, confusion, hallucinations, paranoia, depression, nightmares, insomnia, and rarely, suicidal thoughts or acts may occur; use with caution in patients with known or suspected CNS disorder and use extreme caution in unstable psychiatric illness. Discontinue in patients who experience significant CNS adverse effects. Caution patients not to drive or use machinery if dizziness, fatigue, asthenia, or other CNS effects affecting ability to concentrate or react occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Crystalluria: Rarely, crystalluria has occurred with other quinolones; urine alkalinity may increase the risk. Ensure adequate hydration during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose regulation: Systemic use of fluoroquinolones has been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in in patients with diabetes treated with an oral hypoglycemic agent and/or insulin, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemoptysis: Hemoptysis may occur. Continue treatment in patients with clinically significant hemoptysis only if benefits of treatment outweigh the risks of inducing further hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Unrelated to hypersensitivity, severe hepatotoxicity (including acute hepatitis and fatalities) has been reported with systemically administered levofloxacin (generally within 2 weeks). Elderly patients may be at greater risk. Discontinue therapy immediately if signs and symptoms of hepatitis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: <b>[Canadian Boxed Warning]: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy</b> and have occasionally been fatal. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: Consult an eye specialist if visual disturbances occur; caution patients not to drive or use machinery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Peripheral neuropathy has been reported (rare); may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: <b>[Canadian Boxed Warning]: Seizures may occur; use with extreme caution in individuals predisposed to seizures or with conditions known to lower seizure threshold.</b> Avoid use in patients with a history of epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious adverse reactions: <b>[Canadian Boxed Warning]: </b><b>Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions, including (but not limited to) tendinitis and tendon rupture, peripheral neuropathy, and neuropsychiatric effects.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tendon inflammation/rupture: <b>[Canadian Boxed Warning]: There have been reports of tendon inflammation and/or rupture with quinolone antibiotics; risk may be increased with concurrent corticosteroids, organ transplant recipients, and in patients &gt;60 years.</b> Rupture of the Achilles tendon sometimes requiring surgical repair has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Independent risk factors for tendonitis include strenuous physical activity, renal failure, and previous tendon disorders (eg, rheumatoid arthritis). Discontinue at first sign of tendon inflammation or pain. May occur up to several months after discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: <b>[Canadian Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with myasthenia gravis.</b> Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; not recommended in patients with CrCl &lt;20 mL/min. May increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Adverse effects (eg, hepatotoxicity, tendon rupture, QT changes) may be increased in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[Canadian Boxed Warning]: Data related to use of levofloxacin in pregnancy is limited. In nonclinical studies, fluoroquinolones have been shown to damage weight-bearing cartilage of growing organisms.</b> Consider alternate therapy in pregnant women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For oral inhalation only. Use only with the Zirela Nebulizer system; do not use with any other device. Safety and efficacy of use beyond 6 months (3 consecutive cycles) have not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170687\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170684\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=108311&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Quinolones may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: Quinolones may enhance the adverse/toxic effect of Heroin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Quinolones may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Quinolones may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538451\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[Canadian Boxed Warning]: Data related to use of levofloxacin in pregnancy is limited. In nonclinical studies, fluoroquinolones have been shown to damage weight-bearing cartilage of growing organisms.</b> Other therapies are preferred in pregnant women. Levofloxacin crosses the placenta and can be detected in the amniotic fluid and cord blood following oral or intravenous administration (Ozy&uuml;nc&uuml; 2010a; Ozy&uuml;nc&uuml; 2010b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538452\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[Canadian Boxed Warning]: Levofloxacin may be excreted in breast milk. In nonclinical studies, fluoroquinolones have been shown to damage weight-bearing cartilage of growing organisms.</b> Based on data from a case report, small amounts of levofloxacin are excreted in breast milk following oral and intravenous administration (Cahill 2005). Due to the potential for serious adverse reactions in the breast-feeding infant, the manufacturer recommends a decision be made whether to discontinue breast-feeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538552\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Evaluation of organ system functions (renal, hepatic, and hematopoietic) periodically during therapy; signs/symptoms of hypersensitivity or crystalluria; blood glucose (diabetic patients); bronchospasm or hemoptysis following administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538467\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibition of bacterial DNA gyrase and topoisomerase IV enzymes (both of which are type II topoisomerases) required for DNA replication, transcription, repair and recombination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46538470\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Systemic absorption following multiple dose oral inhalation is approximately equal to that observed following systemic administration of levofloxacin 250 to 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~250 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~30% to 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minimal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 5 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Renal (&gt;85%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49128952\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Quinsair (CZ, DE, DK, EE, GB, HR, IE, LT, PL, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cahill JB Jr, Bailey EM, Chien S, et al. Levofloxacin secretion in breast milk: a case report. <i>Pharmacotherapy</i>. 2005; 25(1):116-118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-united-states-not-available-oral-inhalation-drug-information/abstract-text/15767227/pubmed\" target=\"_blank\" id=\"15767227\">15767227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozy&uuml;nc&uuml; O, Beksac MS, Nemutlu E, Katlan D, Kir S. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. <i>J Obstet Gynaecol Res</i>. 2010a;36(3):484-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-united-states-not-available-oral-inhalation-drug-information/abstract-text/20598025/pubmed\" target=\"_blank\" id=\"20598025\">20598025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozy&uuml;nc&uuml; O, Nemutlu E, Katlan D, Kir S, Beksac MS. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. <i>Int J Antimicrob Agents</i>. 2010b;36(2):175-178.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-united-states-not-available-oral-inhalation-drug-information/abstract-text/20418070/pubmed\" target=\"_blank\" id=\"20418070\">20418070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quinsair (levofloxacin solution for inhalation) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies Inc; September 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-united-states-not-available-oral-inhalation-drug-information/abstract-text/add/pubmed\" target=\"_blank\" id=\"add\">add</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 108311 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46538446\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46538447\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46538485\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991538\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988589\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46538486\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50694805\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46538553\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46538550\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46538448\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F46537812\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46576303\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46538453\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46538459\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46170687\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46170684\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46538451\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46538452\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46538552\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46538467\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46538470\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49128952\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/108311|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levofloxacin-united-states-not-available-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Levofloxacin (United States: Not available) (oral inhalation): Patient drug information \t</a></li></ul></div></div>","javascript":null}